Biotech · Public company · Waltham, MA, US
Cogent Biosciences, Inc.
Ticker COGT · SEC CIK 0001622229
Track this companyFree. Adds Cogent Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials157 recruiting or active
Pipeline programs23From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline23
- CGT9486Phase 3 · Advanced Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 3 · Advanced Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SunitinibPhase 3 · Advanced Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- bezuclastinibPhase 2 · Advanced Systemic Mastocytosis (AdvSM)ClinicalTrials.gov · fetched Nov 12, 2026
- Bezuclastinib Tablets (Formulation A)Phase 2 · SSMClinicalTrials.gov · fetched Nov 12, 2026
- Bezuclastinib Tablets (Formulation B)Phase 2 · SSMClinicalTrials.gov · fetched Nov 12, 2026
- CGT4859Phase 2 · Intrahepatic Cholangiocarcinoma (Icc)ClinicalTrials.gov · fetched Nov 12, 2026
- CGT9486Phase 2 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PexidartinibPhase 2 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SunitinibPhase 2 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ACTR T Cell ProductPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ACTR087Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ACTR087Phase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ACTR707Phase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CGT4255Phase 1 · Advanced Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CGT6297Phase 1 · PIK3CA MutationsClinicalTrials.gov · fetched Nov 12, 2026
- rituximabPhase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- SEA-BCMAPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ACTR T Cell ProductB Cell LymphomasClinicalTrials.gov · fetched Nov 12, 2026
- BezuclastinibSystemic Mastocytoses, IndolentClinicalTrials.gov · fetched Nov 12, 2026
- BezuclastinibGastrointestinal Neoplasms, Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SunitinibGastrointestinal Neoplasms, Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsPHASE1 · RECRUITING · started Jul 23, 2026ClinicalTrials.gov NCT07383506 · fetched Nov 12, 2026
- A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPHASE1 · RECRUITING · started Dec 30, 2025ClinicalTrials.gov NCT07361562 · fetched Nov 12, 2026
- A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 22, 2025ClinicalTrials.gov NCT06777316 · fetched Nov 12, 2026
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GISTPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT06208748 · fetched Nov 12, 2026
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 27, 2022ClinicalTrials.gov NCT05186753 · fetched Nov 12, 2026
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsPHASE3 · RECRUITING · started Apr 14, 2022ClinicalTrials.gov NCT05208047 · fetched Nov 12, 2026
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisPHASE2 · RECRUITING · started Nov 9, 2021ClinicalTrials.gov NCT04996875 · fetched Nov 12, 2026
- Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersPHASE1 · TERMINATED · started Mar 13, 2019ClinicalTrials.gov NCT03680560 · fetched Nov 12, 2026
- Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple MyelomaPHASE1 · TERMINATED · started Feb 22, 2018ClinicalTrials.gov NCT03266692 · fetched Nov 12, 2026
- Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaPHASE1 · TERMINATED · started Oct 4, 2017ClinicalTrials.gov NCT03189836 · fetched Nov 12, 2026
- Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell ProductTERMINATED · started Oct 1, 2016ClinicalTrials.gov NCT02840110 · fetched Nov 12, 2026
- Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaPHASE1 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02776813 · fetched Nov 12, 2026
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Mar 6, 2015ClinicalTrials.gov NCT02401815 · fetched Nov 12, 2026
- Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal TumorsAVAILABLEClinicalTrials.gov NCT06948955 · fetched Nov 12, 2026
- Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisAVAILABLEClinicalTrials.gov NCT06915766 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 8, 2025 · fetched Nov 12, 2026